Hermansky-Pudlak Syndrome
Hermansky-Pudlak syndrome (HPS) is a very rare and complex autosomal recessive disorder defined by three linked features: oculocutaneous albinism (OCA), a platelet function defect that causes a bleeding tendency (bleeding diathesis), and abnormal build-up of ceroid lipofuscin — an indigestible lipid-protein complex — in the reticuloendothelial system, leading to progressive pulmonary fibrosis and granulomatous colitis.
At the molecular level, HPS is not simply a fault in pigment-making enzymes. The problem lies in the structure of lysosome-related organelles (LROs). Mutations in the genes HPS1 through HPS11 disrupt the protein complexes that direct intracellular trafficking, including BLOC-1, BLOC-2, BLOC-3 and AP-3. Because melanosomes, platelet dense granules (delta granules) and lamellar bodies (the surfactant-secreting organelles of type II alveolar cells) are all LROs built by the same biogenesis and packaging machinery, these mutations leave empty, nonfunctional organelles throughout the body.
At Haute-Derma, we classify Hermansky-Pudlak syndrome as high risk in cosmetic dermatology. Skin that lacks protective melanin combined with impaired platelet function makes most invasive procedures and conventional high-heat energy treatments contraindicated. Our approach to HPS focuses on non-contact medical treatments, rigorous photoprotection and tissue-sparing management of epidermal lesions.
A Specialist Medical Approach to Hermansky-Pudlak Syndrome (HPS)
Because HPS can endanger several organs, Haute-Derma follows strict rules for any medical intervention:
- No procedures that injure small blood vessels: we rule out cosmetic treatments that risk bleeding or micro-hemorrhage, such as microneedling, subcision, deep mesotherapy injections or high-strength chemical peels.
- Subtype-specific management: we identify each patient's HPS subtype to predict the risk of internal complications — especially life-threatening pulmonary fibrosis in HPS-1, HPS-2 and HPS-4 — before drawing up any long-term skin care plan.
- A shield against cellular oxidative stress: we focus on potent topical antioxidants to make up for the loss of the skin's own melanin-based defense.
Screening and Clinical Risk Stratification at Haute-Derma
To protect the safety and health of patients with HPS, our pre-treatment diagnostic workup is rigorous:
- Platelet morphology by whole-mount transmission electron microscopy (TEM): the gold standard for diagnosing HPS. It precisely shows the complete absence of platelet dense granules (delta granules), explaining why the platelet count is normal on a complete blood count while primary hemostasis is severely impaired.
- Next-generation sequencing (NGS) gene panel to define the subtype: all 11 HPS-related genes are sequenced. Knowing whether a patient carries an HPS1 or HPS4 mutation is critical, because these subtypes carry a very high risk of developing pulmonary fibrosis in mid-adulthood.
- Screening for organ fibrosis: we coordinate regular spirometry, carbon monoxide diffusing capacity (DLCO) and high-resolution chest CT (HRCT) to catch early alveolar damage from ceroid accumulation.
- Digital dermoscopy to screen for amelanotic tumors: as in the management of generalized albinism, high-resolution dermoscopy is used to monitor the epidermal vascular pattern and detect non-pigmented BCC and SCC early.
Clinical Management and Skin Preservation Protocol at Haute-Derma
Our treatment strategy aims to nourish the skin, support DNA repair and protect tissue without triggering inflammation or bleeding:
- Low-level light therapy (LLLT): a narrow-band medical LED system at 633 nm (red light) and 830 nm (near-infrared) at low energy density. It stimulates the mitochondrial electron transport chain (cytochrome c oxidase), boosts ATP production and supports keratinocyte DNA self-repair, all without heat, vessel injury or bleeding risk.
- Liposomal DNA repair enzymes for the epidermal barrier: topical products containing DNA repair enzymes (such as photolyase and endonuclease) encapsulated in liposomes to cross the skin barrier. These enzymes seek out and remove thymine dimers (UV-induced DNA damage) in the cell nucleus, helping prevent malignant transformation in HPS skin.
- Durable mineral sun protection plus bleeding control: sunscreen with high concentrations of zinc oxide and titanium dioxide (>20%) is mandatory. We also advise oral tranexamic acid (low dose, coordinated with the patient's physician) around dental procedures or minor injuries to help stabilize clots by inhibiting plasminogen.
- Biocompatible topicals for repair: skin-identical lipids — ceramides NP/AP/EOP, cholesterol and free fatty acids — reinforce the mechanical barrier and reduce transepidermal water loss (TEWL), which is especially heavy in skin with impaired epidermal maturation.
